Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 7, 2006 Brian Gorman	Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note.
The Motley Fool May 10, 2006 Brian Gorman	Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now.
The Motley Fool May 4, 2005 Brian Gorman	Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool October 31, 2005 Brian Gorman	Charles River Labs' Seesaw The company is balancing softness in its research models with strength in preclinical services. A wait-and-see attitude toward the stock may be appropriate due to weakness in research models and the company's ambitious expansion plans.
The Motley Fool February 9, 2006 Brian Gorman	Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool July 25, 2011	Digital River Earnings Preview Digital River will unveil its latest earnings on Thursday, July 28.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
The Motley Fool January 31, 2006 Rich Smith	Foolish Forecast: Riding the Digital River Valuation looks good enough here -- especially when you consider just how truly cheap the stock is looking today. Investors, take note.
The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool January 29, 2009	Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool October 31, 2006 Brian Gorman	Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool December 19, 2006 Emil Lee	Steelcase's Iron-Willed Ambitions Can the office-furniture powerhouse double its operating margins by 2010? Investors, take note.
The Motley Fool July 22, 2011	Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again.
The Motley Fool February 5, 2008 Rich Smith	Digital River Roiled Hopes were high in investor-land going into Digital River's fourth-quarter earnings report -- but they were all for naught.
The Motley Fool October 1, 2004 Tom Taulli	Charles River, Outsourced Expert The legal/regulatory and business consulting firm upped its full-year fiscal 2004 guidance, with revenue growth at 30% to 35%. It is good to know the company takes its own advice it gives to clients.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool October 1, 2008 Brian Orelli	WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap.
The Motley Fool July 19, 2007 Rich Duprey	Foolish Forecast: Keeping a Weather Eye on Digital River The e-commerce outsource provider is set to report second-quarter 2007 earnings. Investors, it looks like calmer waters ahead.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool September 23, 2011 Michael Olsen	1 Special Stock Pick From an Outside View Don't fall prey to market myopia. We expect contract researchers -- like Charles River, Icon, and Pharmaceutical Product Development -- to benefit as pharmaceutical companies adopt an increasingly cost-conscious posture.
The Motley Fool October 16, 2006 Rich Smith	Foolish Forecast: American's Wobbly Standard With two earnings misses, a beat, and a match to its credit over the last four quarters, the kitchen and bath fixture-maker hasn't exactly set the standard for consistent outperformance lately. What is in store for the third quarter? Investors, take note.
The Motley Fool August 17, 2005 David Meier	The Power of Margins The way you think about margins can give you an investing edge.
The Motley Fool February 16, 2006 Rich Smith	Foolish Forecast: Talk America Talks Talk America's flat to declining sales, plus fewer profits earned on those sales, is not a recipe for earnings growth. Investors, take note.
The Motley Fool February 1, 2007 Rich Duprey	Foolish Forecast: Digital River Opening New Vistas The e-commerce outsourcing provider is set to report its fourth-quarter 2006 financial results. Investors, here is a look at how strong the current will be.
The Motley Fool August 31, 2006	Foolish Fundamentals: Margins Margins are important, but how you use margin information is more important to your investing success. Don't stay on the surface when analyzing margins. Your portfolio will thank you for it later.
The Motley Fool July 18, 2006 Rich Smith	Foolish Forecast: General Dynamics Forms Ranks The defense contracting powerhouse reports its second-quarter earnings results early tomorrow. Investors, take note.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool July 11, 2006 Anders Bylund	Audiovox More Bark Than Bite The electronics company is delivering on its strategy only in the narrowest sense. Investors may be better off with some of the larger competitors, which have all shown a better ability to manage pricing and margins.
The Motley Fool April 24, 2007 Rich Duprey	Foolish Forecast: Digital River Navigates Choppy Waters The e-commerce outsource provider is set to report first-quarter 2007 financials. Investors, here is what you can expect to see.
The Motley Fool April 28, 2006 Rich Duprey	Digital River's Profitable Sell-Off The market's dismay at the e-commerce provider's guidance may spell opportunity for investors.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool April 25, 2005 Brian Gorman	Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar.
The Motley Fool May 9, 2006 Rich Smith	Foolish Forecast: TOM on the Line TOM Online, one of China's leading Internet portals and wireless service providers, reports its first-quarter 2006 earnings numbers tomorrow.
The Motley Fool October 12, 2004 Rich Duprey	Profit in the Margins Quarterly margin analysis can give you a signal on when to sell.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool April 28, 2005 Mike Cianciolo	Stanley Hammers Away Stanley Works powers ahead with record earnings and sales. Assuming it can improve margins a bit, this stock has a lot to offer investors.
The Motley Fool January 27, 2005 Rich Duprey	Profits Sail at Digital River E-commerce outsourcer posts record profits and earnings.
The Motley Fool October 5, 2006 Nathan Parmelee	New York & Co.: Not as Bad as Advertised Comps may have lagged estimates, but reasons for optimism remain. Investors, take note.
The Motley Fool September 1, 2004 Tom Taulli	Schwab's De-diversification Process The company's foray into diversification has mostly been a failure. Now, it's time to unwind the acquisitions.
The Motley Fool January 25, 2007 Brian Gorman	Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool August 4, 2006 Jim Mueller	O'Charley's Mixed on Margins Improvement in restaurant gross margins is offset by worse operating margins and give mixed results to investors.
InternetNews June 4, 2009 Sean Michael Kerner	Intel Buys Wind River for Embedded Software Intel is acquiring embedded software developer Wind River for $884 million.